Bolt Biotherapeutics, Inc. has announced a significant update regarding its stock ownership. Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have disclosed that they now hold a combined 4.82% of the company's common stock. This development highlights ongoing interest in Bolt Biotherapeutics and reflects the competitive landscape of the pharmaceutical preparations sector.

Background

Bolt Biotherapeutics, Inc. operates in the pharmaceutical preparations industry, specifically under the SIC code 2834. The company trades on the Nasdaq under the ticker symbol BOLT. As an emerging growth company and a smaller reporting company, Bolt Biotherapeutics is focused on developing innovative therapies to address unmet medical needs. Recent filings indicate a proactive approach to maintaining transparency with its investors.

What the Filing Says

The recent filing, a Schedule 13G/A, was submitted on November 12, 2026, and indicates that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have beneficially owned 92,925 shares of Bolt Biotherapeutics. The filing states, "This Schedule 13G is being filed by Renaissance Technologies LLC ('RTC') and Renaissance Technologies Holdings Corporation ('RTHC')." This ownership represents 4.82% of the company's total shares.

Impact

The disclosure of this stake may affect investor sentiment regarding Bolt Biotherapeutics, as it indicates confidence from a well-known investment firm. The involvement of Renaissance Technologies could attract further interest from other institutional investors, potentially impacting the company's market dynamics. As the pharmaceutical preparations sector continues to evolve, such changes in ownership can signal shifts in market confidence and investment strategies.

What's Next

Details were not available in the SEC filing regarding future actions or implications stemming from this ownership stake. Investors and analysts will likely monitor Bolt Biotherapeutics for any further developments or filings that may provide additional insights into the company's strategic direction.